Carlsmed, Inc. (NASDAQ: CARL), an AI-enabled spine surgery firm, saw its stock soar 6.21% in after-hours trading on Wednesday, marking a significant reversal from its earlier performance during its Nasdaq debut. The company, which had just completed its initial public offering (IPO), raised $100.5 million by selling 6.7 million shares at $15 each, the midpoint of its marketed range.
The stock's after-hours rally comes as a contrast to its earlier performance. During regular trading hours, Carlsmed shares had fallen as much as 6.7% from their IPO price, closing at $14.57, down 2.8% from the offering price. This initial decline was likely due to broader market conditions and investor caution surrounding newly listed companies.
Founded in 2018, Carlsmed is a commercial-stage medical technology company focused on pioneering AI-enabled personalized spine surgery solutions. The successful completion of its IPO, despite the initial stock price decline, demonstrates investor interest in innovative medical technology firms. The after-hours surge may indicate that investors are reassessing the company's potential in the growing field of AI-assisted medical procedures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.